Medtronic plc (MDT) operating KPIs
MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026Score 19/303% below fair value
$96.54−0.57 (-0.59%)
Close on Oct 30, 2026Market cap $123.49BP/E 23.7Yield 2.94%
Medtronic miniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) ($M)
MiniMed Group, Inc. (CIK 0002062583) Form 10-K/10-Q/8-K/424B4 & FY26Q4 / Sept 2026 Presentations
Latest, Q1 FY27
843
Period ended Jul 31, 2026
Change on a year earlier
+16.6%
723 in Q1 FY26
History
9 quarters
Since Q1 FY25
Sources
1
MiniMed Group Investor Presentation (September 2026)
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 FY27 | Jul 31, 2026 | 843 | +16.6% | MiniMed Group Investor Presentation (September 2026) ↗ |
| Q4 FY26 | Apr 30, 2026 | 837 | +15.6% | MiniMed Group Investor Presentation (September 2026) ↗ |
| Q3 FY26 | Jan 31, 2026 | 790 | +15.0% | MiniMed Group Investor Presentation (September 2026) ↗ |
| Q2 FY26 | Oct 31, 2025 | 752 | +10.3% | MiniMed Group Investor Presentation (September 2026) ↗ |
| Q1 FY26 | Jul 31, 2025 | 723 | +16.1% | MiniMed Group Investor Presentation (September 2026) ↗ |
| Q4 FY25 | Apr 30, 2025 | 724 | – | MiniMed Group Investor Presentation (September 2026) ↗ |
| Q3 FY25 | Jan 31, 2025 | 687 | – | MiniMed Group Investor Presentation (September 2026) ↗ |
| Q2 FY25 | Oct 31, 2024 | 682 | – | MiniMed Group Investor Presentation (September 2026) ↗ |
| Q1 FY25 | Jul 31, 2024 | 623 | – | MiniMed Group Investor Presentation (September 2026) ↗ |
Breakdown
What makes up minimed group, inc. (nasdaq: mmed) — standalone net sales ($m)
- MiniMed — Organic Revenue Growth YoY (%)15.8% · Q1 FY27
- MiniMed — U.S. Net Sales ($M)240 · Q1 FY27
- MiniMed — International Net Sales ($M)603 · Q1 FY27
- MiniMed — Adjusted Standalone EBITDA ($M)83 · Q1 FY27
- MiniMed — Adjusted EBITDA ($M)83 · Q1 FY27
- MiniMed — Adjusted Gross Profit ($M)471 · Q1 FY27
- MiniMed — Adjusted Standalone Operating Income ($M)-68 · Q4 FY26
- MiniMed — Adjusted Standalone Net Income ($M)-53 · Q4 FY26
- MiniMed — GAAP Gross Profit ($M)465 · Q1 FY27
- MiniMed — GAAP R&D Expense ($M)115 · Q1 FY27
- MiniMed — GAAP SG&A Expense ($M)312 · Q1 FY27
- MiniMed — GAAP Operating Income / (Loss) ($M)5 · Q1 FY27
- MiniMed — GAAP Net Income / (Loss) ($M)0 · Q1 FY27
- MiniMed — Standalone Inventories ($M)356 · Q1 FY27
- MiniMed — Standalone Remaining Performance Obligations ($M)46 · Q1 FY27
- MiniMed — Standalone Contract Liabilities ($M)19 · Q1 FY27
- MiniMed — Customer Refund & Return Liabilities ($M)42 · Q1 FY27
- MiniMed — Property, Plant & Equipment, Net ($M)736 · Q1 FY27
- MiniMed — Goodwill ($M)2,300 · Q1 FY27
Cite this data
StockData. (2026). Medtronic MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) ($M), quarterly Q1 FY25–Q1 FY27 [Data set]. Compiled from Medtronic SEC filings and investor materials. https://stockdatahq.com/stocks/mdt/kpis/mmed-sub-rev
See every metric in the Medtronic KPI table. Data updated Oct 31, 2026.